1036756-03-2

Basic information

• Product Name: 6-Amino-3-bromo-2-fluoro-benzoic acid
• Synonyms: 6-Amino-3-bromo-2-fluoro-benzoic acid
• CAS NO: 1036756-03-2
• Molecular Formula: C7H5BrFNO2
• Molecular Weight: 234.0225032
• Mol File: 1036756-03-2.mol

Chemical Properties

• Boiling Point: 335.3±42.0 °C(Predicted)
• Appearance: /
• Density: 1.877±0.06 g/cm3(Predicted)
• PKA: 3.62±0.10(Predicted)
• CAS DataBase Reference: 6-Amino-3-bromo-2-fluoro-benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Amino-3-bromo-2-fluoro-benzoic acid(1036756-03-2)
• EPA Substance Registry System: 6-Amino-3-bromo-2-fluoro-benzoic acid(1036756-03-2)

Safety Data

• Hazardous Substances Data: 1036756-03-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Amino-3-bromo-2-fluoro-benzoic acid is used as an intermediate for the synthesis of anti-inflammatory and analgesic drugs, contributing to the development of medications that alleviate pain and reduce inflammation.
Used in Organic Compounds Synthesis:
It serves as a key intermediate in the production of dyes and pigments, enhancing the color properties and stability of these compounds in various applications.
Safety Considerations:
6-Amino-3-bromo-2-fluoro-benzoic acid is considered potentially hazardous if ingested or inhaled, necessitating careful handling and appropriate safety measures during its use and production.

Upstream product

• 845866-92-4 6-amino-3-bromo-2-fluorobenzonitrile 
• 434-76-4 2-amino-6-fluorobenzoic acid 

Downstream Products

• 1036756-07-6 6-bromo-2-chloro-5-fluoroquinazoline 

Relevant articles and documents

PLASMA KALLIKREIN INHIBITORS AND USES THEREOF

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF

Spirocyclic 2,3-dihydro-7-azaindole compounds of formula (I), variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the spirocyclic 2,3-dihydro-7-azaindole compounds.

Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)

Hematopoietic progenitor kinase 1 (HPK1) is implicated as a negative regulator of T-cell receptor-induced T-cell activation. Studies using HPK1 kinase-dead knock-in animals have demonstrated the loss of HPK1 kinase activity resulted in an increase in T-cell function and tumor growth inhibition in glioma models. Herein, we describe the discovery of a series of small molecule inhibitors of HPK1. Using a structure-based drug design approach, the kinase selectivity of the molecules was significantly improved by inducing and stabilizing an unusual P-loop folded binding mode. The metabolic liabilities of the initial 7-azaindole high-throughput screening hit were mitigated by addressing a key metabolic soft spot along with physicochemical property-based optimization. The resulting spiro-azaindoline HPK1 inhibitors demonstrated improved in vitro ADME properties and the ability to induce cytokine production in primary human T-cells.

ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF

The disclosure relates to compounds that act as allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.

Quinazolinone Compound and Application Thereof

The present invention relates to a series of quinazolinone compounds and applications thereof as PI3Kα inhibitors. In particular, the present invention relates to a compound shown in formula (I) and a tautomer or pharmaceutically acceptable salt thereof.

DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY

Provided herein are compounds of the Formula (I), (II), and (III), as well as pharmaceutically acceptable salts thereof, wherein the substituents are those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of oncologic diseases.

AZAINDOLES AS INHIBITORS OF HPK1

Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1- dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.